Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well understood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-opti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuczynski, Elizabeth A., Kerbel, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124233/
https://www.ncbi.nlm.nih.gov/pubmed/27887628
http://dx.doi.org/10.1186/s40880-016-0162-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124233/
https://www.ncbi.nlm.nih.gov/pubmed/27887628
http://dx.doi.org/10.1186/s40880-016-0162-7

Ejemplares similares